These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 20149156

  • 1. A probable case of transfusion-transmitted hepatitis B virus infection in an immunosuppressed recipient caused by an occult HBV-infected donor with negative ID-NAT.
    Leung VK, Lee CK, Chau TN, Cheung WI, Lo FH, Lai KB, Lin CK.
    Transfus Med; 2010 Aug 01; 20(4):276-7. PubMed ID: 20149156
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Occult hepatitis B virus infection.
    Allain JP.
    Transfus Clin Biol; 2004 Feb 01; 11(1):18-25. PubMed ID: 14980545
    [Abstract] [Full Text] [Related]

  • 4. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP, REDS Study Group.
    Transfusion; 2004 Sep 01; 44(9):1332-9. PubMed ID: 15318857
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Occult hepatitis B virus infection among anti-HBc positive blood donors: Necessitates substitution of screening by HBV NAT.
    Panhotra BR, Bahrani A, Joshi CS, ul Hassan Z.
    J Infect; 2005 Oct 01; 51(3):263. PubMed ID: 16125778
    [No Abstract] [Full Text] [Related]

  • 9. Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.
    Kiely P, Margaritis AR, Seed CR, Yang H, Australian Red Cross Blood Service NAT Study Group.
    Transfusion; 2014 Aug 01; 54(8):2084-91. PubMed ID: 24650170
    [Abstract] [Full Text] [Related]

  • 10. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.
    Martin LA, Stramer SL, Kuhns MC, Schlauder GG.
    Transfusion; 2012 Oct 01; 52(10):2201-8. PubMed ID: 22321072
    [Abstract] [Full Text] [Related]

  • 11. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP.
    Vox Sang; 2004 Feb 01; 86(2):83-91. PubMed ID: 15023176
    [Abstract] [Full Text] [Related]

  • 12. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K.
    Transfusion; 2007 Jul 01; 47(7):1197-205. PubMed ID: 17581154
    [Abstract] [Full Text] [Related]

  • 13. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage.
    Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, Ohnuma H, Miyakawa K, Tachibana K, Mizoguchi H, Japanese Red Cross NAT Screening Research Group.
    Transfusion; 2007 Jul 01; 47(7):1162-71. PubMed ID: 17581150
    [Abstract] [Full Text] [Related]

  • 14. Detection of an acute asymptomatic HBsAg negative hepatitis B virus infection in a blood donor by HBV DNA testing.
    Weber B, Mühlbacher A, Melchior W.
    J Clin Virol; 2005 Jan 01; 32(1):67-70. PubMed ID: 15572009
    [Abstract] [Full Text] [Related]

  • 15. Occult hepatitis B infection and transfusion-transmission risk.
    Candotti D, Boizeau L, Laperche S.
    Transfus Clin Biol; 2017 Sep 01; 24(3):189-195. PubMed ID: 28673499
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
    Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, Chiacchierini RP, Pietrelli LA.
    Transfusion; 2005 Aug 01; 45(8):1247-57. PubMed ID: 16078909
    [Abstract] [Full Text] [Related]

  • 17. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R.
    Transfusion; 2009 Jun 01; 49(6):1115-25. PubMed ID: 19309474
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases.
    Laperche S, Maniez M, Barlet V, El Ghouzzi MH, Le Vacon F, Levayer T, Lunel F, Morel P, Mouillot L, Piquet Y, Pillonel J, Transfusion-Transmissible Agents Working Group, French National Society of Blood Transfusion.
    Transfusion; 2008 Nov 01; 48(11):2308-14. PubMed ID: 18673347
    [Abstract] [Full Text] [Related]

  • 20. Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.
    Bouchardeau F, Girault A, Razer A, Servant-Delmas A, Mercier M, Laperche S.
    Transfusion; 2006 Dec 01; 46(12):2047-52. PubMed ID: 17176315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.